Match!
Kevin Marsh
Multiple-criteria decision analysisHealth careDecision analysisManagement scienceMedicine
31Publications
8H-index
609Citations
What is this?
Publications 33
Newest
Last. Roberto T. Zori (UF: University of Florida)H-Index: 29
view all 8 authors...
Abstract Background Phenylketonuria (PKU) leads to an accumulation of phenylalanine (Phe) in the blood and subsequent neurologic, cognitive, psychiatric, and behavioral dysfunction. Many patients report social isolation and decreased quality of life. Pegvaliase is an enzyme substitution therapy that reduces blood Phe levels in patients with PKU and is associated with a risk of hypersensitivity reactions. Objective To define the minimum acceptable benefit (MAB) of pegvaliase, i.e., the minimum pr...
1 CitationsSource
#1Rob Baltussen (Radboud University Nijmegen)H-Index: 41
#2Kevin MarshH-Index: 8
Last. Henk Broekhuizen (Radboud University Nijmegen)H-Index: 4
view all 23 authors...
Abstract Objective Recent years have witnessed an increased interest in the use of multicriteria decision analysis (MCDA) to support health technology assessment (HTA) agencies for setting healthcare priorities. However, its implementation to date has been criticized for being “entirely mechanistic,” ignoring opportunity costs, and not following best practice guidelines. This article provides guidance on the use of MCDA in this context. Methods The present study was based on a systematic review ...
Source
#1Cathy Anne Pinto (MSD: Merck & Co.)H-Index: 6
#2Tommi TervonenH-Index: 19
Last. Tarek A. Hammad (MSD: Merck & Co.)H-Index: 28
view all 9 authors...
PURPOSE: Quantitative benefit-risk (B-R) assessments are used to characterize treatment by combining key benefits and risks into a single metric but have historically been done for the "average" patient. Our aim was to conduct an individualized assessment for the oral antiplatelet vorapaxar by combining trial and real-world data to further personalize the treatment profiles. METHODS: Using linked UK health care databases, we developed risk prediction equations for key ischemic and bleeding event...
1 CitationsSource
Source
#1Kevin MarshH-Index: 8
#2Praveen Thokala (University of Sheffield)H-Index: 19
Last. Kalipso Chalkidou (Imperial College London)H-Index: 8
view all 4 authors...
Background Multicriteria decision analysis (MCDA) has the potential to bring more structure and transparency to health technology assessment (HTA). The objective of this paper is to highlight key methodological and practical challenges facing the use of MCDA for HTA, with a particular focus on lower and middle-income countries (LMICs), and to highlight potential solutions to these challenges.
2 CitationsSource
Source
#1S. Sri BhashyamH-Index: 1
#2Adrian QuartelH-Index: 6
Last. Kevin MarshH-Index: 8
view all 5 authors...
1 CitationsSource
#1Tommi TervonenH-Index: 2
#2Tabea Schmidt-Ott (Lond: University of London)H-Index: 1
Last. Ellen M. Janssen (Johns Hopkins University)H-Index: 8
view all 6 authors...
Abstract Background Dominance tests are often applied to test for the rationality in the choice behavior of participants in discrete-choice experiments (DCEs). Objectives To examine how dominance tests have been implemented in recent DCE applications in health and discuss their theoretical and empirical interpretation. Methods Health-related DCEs published in 2015 were reviewed for the inclusion of tests on choice behavior. For studies that implemented a dominance test, information on applicatio...
1 CitationsSource
#1Kevin MarshH-Index: 8
#2J. Jaime Caro (McGill University)H-Index: 55
Last. Alaa Hamed (Genzyme)H-Index: 4
view all 5 authors...
Objectives: Patient preferences should be a central consideration in healthcare decision making. However, stories of patients challenging regulatory and reimbursement decisions has led to questions on whether patient voices are being considered sufficiently during those decision making processes. This has led some to argue that it is necessary to quantify patient preferences before they can be adequately considered. Methods: This study considers the lessons from the use of multi-criteria decisio...
3 CitationsSource
#1Tommi TervonenH-Index: 2
#2Anastasia Ustyugova (Boehringer Ingelheim)H-Index: 3
Last. Kevin MarshH-Index: 8
view all 9 authors...
Abstract Background Decision on the most appropriate oral anticoagulation therapy for stroke prevention in patients with nonvalvular atrial fibrillation is difficult because multiple treatment options are available, and these vary in their clinical effects and relevant nonclinical characteristics. Objectives To use a multicriteria decision analysis (MCDA) to compare the oral anticoagulants apixaban, dabigatran, edoxaban, rivaroxaban, and vitamin K antagonist (VKAs; specifically warfarin) in pati...
3 CitationsSource
1234